Edition:
United Kingdom

Oramed Pharmaceuticals Inc (ORMP.OQ)

ORMP.OQ on NASDAQ Stock Exchange Capital Market

4.76USD
17 Aug 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$4.76
Open
$4.74
Day's High
$4.76
Day's Low
$4.68
Volume
1,373
Avg. Vol
8,217
52-wk High
$11.34
52-wk Low
$4.68

Latest Key Developments (Source: Significant Developments)

Oramed Granted Japanese Patent For GLP-1 Analog Capsule
Tuesday, 24 Jul 2018 

July 24 (Reuters) - Oramed Pharmaceuticals Inc ::ORAMED GRANTED JAPANESE PATENT FOR GLP-1 ANALOG CAPSULE.  Full Article

Oramed Announces $18.1 Mln Registered Direct Offering
Tuesday, 3 Jul 2018 

July 3 (Reuters) - Oramed Pharmaceuticals Inc ::ORAMED ANNOUNCES $18.1 MILLION REGISTERED DIRECT OFFERING.ENTERED INTO DEFINITIVE AGREEMENTS WITH SEVERAL HEALTHCARE-FOCUSED INSTITUTIONAL INVESTORS.ORAMED PHARMACEUTICALS- AGREEMENTS FOR BUY 2.9 MILLION SHARES OF ITS STOCK AND WARRANTS TO PURCHASE UP TO 2.9 MILLION SHARES OF ITS COMMON STOCK.REGISTERED DIRECT OFFERING AT A COMBINED PURCHASE PRICE OF $6.25 PER SHARE AND RELATED WARRANTS.  Full Article

Oramed receives approval for clinical study to treat NASH
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Oramed Pharmaceuticals Inc :Oramed receives regulatory approval to conduct clinical study for treatment of NASH with its oral insulin capsule.Israel's ministry of health granted company approval to initiate exploratory clinical study of ORMD-0801 in patients with NASH​.Proposed study will assess effectiveness of ORMD-0801 in reducing liver fat content, inflammation and fibrosis in patients with NASH​.Says ‍plans on initiating study in coming month​.  Full Article

BRIEF-Oramed Initiates Its 90-Day Pivotal Dose-Ranging Clinical Study For Oral Insulin

* ORAMED INITIATES ITS 90-DAY PIVOTAL DOSE-RANGING CLINICAL STUDY FOR ORAL INSULIN Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)